Beta blocker effects on plasma homocysteine levels in patients with hypertension
- PMID: 16039296
- DOI: 10.1016/j.atherosclerosis.2005.01.035
Beta blocker effects on plasma homocysteine levels in patients with hypertension
Abstract
Recent studies have shown that hyperhomocysteinemia might play a role in the pathogenesis of hypertension. The effects of antihypertensive agents on plasma homocysteine levels have not been tested extensively. We investigated the effects of beta-blocker therapy on homocysteine levels in patients with hypertension. In the study, 120 patients with newly diagnosed hypertension were enrolled. All patients received metoprolol succinate 100 mg/day initially. If blood pressure was above normal on the 15th day of follow-up, the metoprolol dosage was doubled. Before initiation of the antihypertensive medication and after the fourth month of treatment, homocysteine levels were measured. Of the 120 patients enrolled, 39 could not complete the study. Homocysteine levels decreased significantly by the end of the fourth month when compared with basal values (13.5+/-4.5 micromol/l versus 12.4+/-4.9 micromol/l; P = 0.001). There was no relation between homocysteine level and blood pressure control. There was a significant decrease in homocysteine levels in the women treated in this study (P = 0.001); however, this effect was absent in men (P = 0.185). We demonstrate that metoprolol succinate treatment significantly decreases plasma homocysteine levels in patients with hypertension, especially in women.
Similar articles
-
Effects of a beta blocker and spironolactone on plasma homocysteine levels.Int J Cardiol. 2003 Oct;91(2-3):259-60. doi: 10.1016/s0167-5273(03)00034-2. Int J Cardiol. 2003. PMID: 14559143 No abstract available.
-
Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.Anadolu Kardiyol Derg. 2007 Dec;7(4):383-7. Anadolu Kardiyol Derg. 2007. PMID: 18065333 Clinical Trial.
-
A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).Am J Hypertens. 2006 Apr;19(4):388-95. doi: 10.1016/j.amjhyper.2005.10.007. Am J Hypertens. 2006. PMID: 16580575 Clinical Trial.
-
Metoprolol succinate combination in the treatment of hypertension.Angiology. 2009 Oct-Nov;60(5):608-13. doi: 10.1177/0003319708326450. Epub 2008 Nov 24. Angiology. 2009. PMID: 19033265 Review.
-
Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.Z Kardiol. 2004 Jun;93(6):439-53. doi: 10.1007/s00392-004-0075-3. Z Kardiol. 2004. PMID: 15252738 Review.
Cited by
-
Homocysteine as a risk factor for hypertension: a 2-year follow-up study.PLoS One. 2014 Oct 13;9(10):e108223. doi: 10.1371/journal.pone.0108223. eCollection 2014. PLoS One. 2014. PMID: 25310282 Free PMC article.
-
Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.Vasc Health Risk Manag. 2007;3(1):99-108. Vasc Health Risk Manag. 2007. PMID: 17583180 Free PMC article. Review.
-
Efficacy of metoprolol plus atorvastatin for carotid atherosclerosis and its influence on carotid intima-media thickness and homocysteine level.Am J Transl Res. 2022 Aug 15;14(8):5511-5519. eCollection 2022. Am J Transl Res. 2022. PMID: 36105018 Free PMC article.
-
Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature.Diagnostics (Basel). 2022 Sep 9;12(9):2192. doi: 10.3390/diagnostics12092192. Diagnostics (Basel). 2022. PMID: 36140593 Free PMC article.
-
Effect of enalapril on plasma homocysteine levels in patients with essential hypertension.J Zhejiang Univ Sci B. 2010 Aug;11(8):583-91. doi: 10.1631/jzus.B1001003. J Zhejiang Univ Sci B. 2010. PMID: 20669348 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical